ONCORED
An unrivalled medical device based on red- light photo biomodulation to prevent, improve and remove oral mucositis and dermatitis chemo radio induced as a side effect of cancer treatment
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ONCORED project word cloud
Explore the words cloud of the ONCORED project. It provides you a very rough idea of what is the project "ONCORED" about.
Project "ONCORED" data sheet
The following table provides information about the project.
| Coordinator |
NEOMEDLIGHT
Organization address contact info |
| Coordinator Country | France [FR] |
| Project website | https://www.neomedlight.com/therapy-and-light |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-08-01 to 2018-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | NEOMEDLIGHT | FR (VILLEURBANNE) | coordinator | 50˙000.00 |
Map
Project objective
Today the healthcare system is under great pressure, suffering the challenges brought by cancer and the ageing of the population. Among these challenges is the need for treating oral mucositis (OM) and dermatitis. Both are considered as adverse effects of radio and chemo-therapy employed during the treatment of some cancers, specially leukaemia, head & neck cancers and breast cancers which only generate dermatitis. There is an increase incidence of cancers worldwide, for instance, 842,000 new cases of head and neck cancer were diagnosed in 2017. In addition, leukaemia counts with around 352,000 new cases diagnosed in 2015. And breast cancer is the second most common cancer with 1.7 million new cancer cases diagnosed in the year 2015. These inflammations, occur in 100% of patients that are receiving chemotherapy highâ€dose. In views of the situation, there is an urgent need to treat these chemo and radio therapy-associated diseases but the current medical devices are ill adapted since the radiation emitted cannot be controlled in a homogenous way, resulting in an inefficient treatment of OM and dermatitis. In response, NEOMEDLIGHT have developed ONCORED, an innovative medical device based on photo biomodulation for the non-harmful treatment of oral mucositis and dermatitis. ONCORED seeks to simplify workflows at the clinical level enabling the prevention, improvement and removal of OM and dermatitis with homogenous red-light whose dose (energy and power) can be well controlled. Having validated the reliability of the ONCORED system at the pilot scale, we now want to finalise its development and achieve market preparedness. In Phase 1 we aim to carry a Feasibility Study to warrant the project from a technical, commercial and financial point of view. Besides the crucial benefits that it will bring to healthcare, ONCORED will boost the growth of NEOMEDLIGHT, expecting to gain € 27 million gross profit and 16 new people after 5 years in the market, reaching a ROI of 5.49.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCORED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ONCORED" are provided by the European Opendata Portal: CORDIS opendata.